Introduction
Mitral valve surgery has historically been the treatment of choice for many patients with severe symptomatic mitral regurgitation (MR) due to primary degenerative valve disease and less often for those with secondary functional MR. However, nearly half of patients with significant MR are not offered therapy due to prohibitive surgical risk [1] . As a result, transcatheter therapies have been developed to treat symptomatic MR in these patients.
The MitraClip system (Abbott Vascular, Santa Clara CA) is an FDA-approved transcatheter therapy for high-risk patients with severe symptomatic MR. There remain significant technical challenges to the MitraClip procedure particularly in those patients with complex mitral valve anatomy. Challenging scenarios could include patients with wide flail gaps, focal or diffuse calcification, restricted leaflets, and the presence of clefts or deep scallops which can interfere with leaflet grasping. When significant residual MR exists and additional MitraClips are not anatomically feasible, current options are limited.
Successful implantation of the MitraClip and determination of the number of clips needed is highly dependent on valve leaflet anatomy and degree of resultant regurgitation or stenosis observed intra-procedurally after deployment of each clip. Mechanistically, the MitraClip system involves active grasping of both leaflets, which ensures security and enhances native leaflet coaptation. However, variable leaflet anatomy consisting of clefts or degenerated leaflet anatomy risks leaving residual jets between clips. The Amplatzer Vascular Plug (AVP) II and Amplatzer Duct Occluder (ADO) II devices, both constructed of a self-expanding nitinol mesh have been used to occlude residual regurgitant jets after MitraClip therapy. This case highlights a unique treatment strategy for intra-clip residual MR with the utilization of the AVP II device.
Case Report
An 88-year-old male with severe aortic stenosis, severe primary mitral regurgitation due to a flail posterior leaflet, diastolic heart failure (ejection fraction 70%), hypertension, type II diabetes mellitus, and hyperlipidemia presented to our emergency department with sudden onset of palpitations and chest pressure. He had developed NYHA III symptoms approximately three months prior to admission, with intermittent, progressive, lower extremity edema and dyspnea on exertion. On admission, he was found to be in rapid atrial fibrillation and in acute congestive heart failure exacerbation. He underwent transesophageal echocardiography (TEE) with direct current cardioversion and was placed on atrioventricular nodal agents and rhythm suppressive therapy with beta-blockers and amiodarone. Pre-procedure catheterization revealed no significant coronary artery disease, and hemodynamics were significant for: mean right atrial pressure 20 mm Hg, mean pulmonary artery pressure of 34 mm Hg, mean wedge pressure of The investigators demonstrated significant, acute MR reduction using the ADO II device in all 9 patients [6] .
Potential limitations and risks of occluder therapy do exist. These include inappropriate device sizing, device embolization, hemolysis, and leaflet erosion. In order to prevent many of the aforementioned complications, defining the location and size of the residual regurgitant jets through fluoroscopy, echocardiography, and clinical judgment is of utmost importance. In all 9 patients, Kubo showed MR reduced to < 2+, with decreases in left atrial pressure and normalization of systolic pulmonary vein flow. Importantly, there was no increase in the transmitral diastolic gradient after ADO II deployment, nor was there evidence of hemolysis. One significant complication did arise during this technique, which involved ADO II embolization into the right coronary artery, resulting in an inferior ST-segment elevation myocardial infarction 9 hours after the procedure. Although the mechanism was not clear, it is presumed that the device was undersized to that of the defect or that leaflet integrity at the occluder location was suboptimal.
An additional application of the AVP II has been seen in treatment of paravalvular leak (PVL), a frequent complication after the implantation of a prosthetic valve. Due to the high risk associated with surgical re-operation to close the defect or replace the prosthesis, the development of newer devices, including the AVP II and III, have been proposed as an alternate strategy for percutaneous closure. In a recent study by Sanchez-Recalde et al., closure was attempted for 23 PVL (17 mitral and 6 aortic). In mitral PVL, the first option was to implant an AVP III device, although in some cases an ADO was finally used due to the morphology, PVL size, or interference of the AVP III with a disc in the prosthesis. When choosing the device the largest and smallest diameters of the defect were measured with 3-D TEE reconstruction, and a device equal to, or 1-2 mm larger than the defect was used. Overall, the ADO II was used in 2 (9%) of cases, while the AVP II was used in 18 (86%) of cases [7] . In our case the AVP II was utilized rather than the ADO II occluder due to the side availability of diameters, ranging from 3 to 22 mm. The ADO II occluder has waist sizes of only 5 and 6 mm and it was felt this was too small for the defect. In regards to structure, the most significant difference between the AVP II and ADO devices is the difference in size between the retention discs disc and central waist. The ADO has a 4-6 mm difference, while the AVP II device has a similar size; this may, theoretically, contribute to better anchoring of the AVP II device.
In summary, given the relatively limited clinical experience with the use of occluder devices for the treatment of residual MR after MitraClip therapy, operators should always adopt a "MitraClip first" and "occluder second only if needed" approach. Whether or not performing occluder therapy at the time of the index procedure is superior to a later staged procedure is not known. It appears that the main early risk is device embolization, which may be mitigated by performing a gentle "tug test" prior to device release.
Conclusion
In conclusion, we have shown a novel and effective intra-procedural treatment option for inter-clip MR, particularly can be utilized in treatment of substantial inter-clip MR. Given the relatively limited clinical experience, the procedure is heavily operator dependent; it is encouraged to utilize 3D reconstruction for pre-procedural planning and discuss risks and benefits with the patient prior to the procedure.
